A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

274

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

DRUG: Faricimab

Sponsor

Hoffmann-La Roche